Phillip Schneider

Gen-Probe, Inc. develops, manufactures and markets rapid, accurate and molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. It also develops and manufactures the PROCLEIX assays, which are used to detect human immunodeficiency virus, the hepatitis C virus, the hepatitis B virus, and the West Nile virus in donated human blood. The firm's clinical diagnostics products include APTIMA family of assays, which are used to detect the common STDs chlamydia and gonorrhea. Gen-Probe was founded by Thomas H. Adams and David E. Kohne in 1983 and is headquartered in San Diego, CA.

IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA.

TargeGen, Inc. manufactures vascular biopharmaceutical products. The company was founded by David A. Cheresh and Peter G. Ulrich in 2001 and is headquartered in San Diego, CA.

Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT.

Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA.